Skip to main content

ERRATUM article

Front. Oncol., 05 November 2024
Sec. Genitourinary Oncology
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1516456
This article is part of the Research Topic Advances in Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer View all 5 articles

Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

This article is an erratum on:

  1. Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An erratum on
Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

By Fattahi MR, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B, Oroomi TR, Motedayyen H and Arefnezhad R (2024). Front. Oncol. 14:1438297. doi: 10.3389/fonc.2024.1438297

Due to a production error, there was an error in affiliation 1. Instead of “School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran”, it should be “Student Research Committee, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran”. The publisher apologizes for this mistake.

The original version of this article has been updated.

Keywords: nanomedicine, nanoparticle, urology, cancer, treatment, clinical, biosafety

Citation: Frontiers Production Office (2024) Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers. Front. Oncol. 14:1516456. doi: 10.3389/fonc.2024.1516456

Received: 24 October 2024; Accepted: 24 October 2024;
Published: 05 November 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

Copyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.